Cellular immunity plays a major role in the control of human cytomegalovirus (HCMV) infection. CD4+ T lymphocytes have been shown to contribute to this function but their precise role is a matter of debate. Although CD4+ T cells have been shown to kill target cells through the perforin/granzyme pathway, whether HCMV-specific CD4+ T cells are capable of killing HCMV-infected targets has not yet been documented. In the present paper, we have taken advantage of well established cellular reagents to address this issue. Human CD4+ T-cell clones specific for the major immediate-early protein IE1 were shown to perform perforin-based cytotoxicity against peptide-pulsed targets. However, when tested on infected anitgen presenting cell targets, cytotoxicity was not detectable, although gamma interferon (IFN-γ) production was significant. Furthermore, cytotoxicity against peptide-pulsed targets was inhibited by HCMV infection, whereas IFN-γ production was not modified, suggesting that antigen processing was not altered. Remarkably, degranulation of CD4+ T cells in the presence of infected targets was significant. Together, our data suggest that impaired cytotoxicity is not due to failure to recognize infected targets but rather to a mechanism specifically related to cytotoxicity.
AdhikaryD.,
BehrendsU.,
MoosmannA.,
WitterK.,
BornkammG. W.,
MautnerJ.2006; Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med 203:995–1006[CrossRef]
BettsM. R.,
BrenchleyJ. M.,
PriceD. A.,
De RosaS. C.,
DouekD. C.,
RoedererM.,
KoupR. A.2003; Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78[CrossRef]
BettsM. R.,
PriceD. A.,
BrenchleyJ. M.,
LoreK.,
GuenagaF. J.,
Smed-SorensenA.,
AmbrozakD. R.,
MiguelesS. A.,
ConnorsM.other authors2004; The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 172:6407–6417[CrossRef]
BissingerA. L.,
SinzgerC.,
KaiserlingE.,
JahnG.2002; Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J Med Virol 67:200–206[CrossRef]
CebullaC. M.,
MillerD. M.,
ZhangY.,
RahillB. M.,
ZimmermanP.,
RobinsonJ. M.,
SedmakD. D.2002; Human cytomegalovirus disrupts constitutive MHC class II expression. J Immunol 169:167–176[CrossRef]
DavignonJ. L.,
CastanieP.,
YorkeJ. A.,
GautierN.,
ClementD.,
DavrincheC.1996; Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro. J Virol 70:2162–2169
EinseleH.,
RoosnekE.,
RuferN.,
SinzgerC.,
RieglerS.,
LofflerJ.,
GrigoleitU.,
MorisA.,
RammenseeH.other authors2002; Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916–3922[CrossRef]
ElkingtonR.,
KhannaR.2005; Cross-recognition of human alloantigen by cytomegalovirus glycoprotein-specific CD4+ cytotoxic T lymphocytes: implications for graft-versus-host disease. Blood 105:1362–1364
FierzW.,
EndlerB.,
ReskeK.,
WekerleH.,
FontanaA.1985; Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:3785–3793
GamadiaL. E.,
RemmerswaalE. B.,
WeelJ. F.,
BemelmanF.,
van LierR. A.,
Ten BergeI. J.2003; Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:2686–2692[CrossRef]
GautierN.,
ChavantE.,
PrieurE.,
MonsarratB.,
MazarguilH.,
DavrincheC.,
GairinJ. E.,
DavignonJ. L.1996; Characterization of an epitope of the human cytomegalovirus protein IE1 recognized by a CD4+ T cell clone. Eur J Immunol 26:1110–1117[CrossRef]
GavinM. A.,
GilbertM. J.,
RiddellS. R.,
GreenbergP. D.,
BevanM. J.1993; Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol 151:3971–3980
GyulaiZ.,
EndreszV.,
BurianK.,
PincusS.,
ToldyJ.,
CoxW. I.,
MericC.,
PlotkinS.,
GonczolE.,
BerencsiK.2000; Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181:1537–1546[CrossRef]
HegdeN. R.,
DunnC.,
LewinsohnD. M.,
JarvisM. A.,
NelsonJ. A.,
JohnsonD. C.2005; Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J Exp Med 202:1109–1119[CrossRef]
HemmerB.,
StefanovaI.,
VergelliM.,
GermainR. N.,
MartinR.1998; Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 160:5807–5814
HopkinsJ. I.,
FianderA. N.,
EvansA. S.,
DelchambreM.,
GheysenD.,
BorysiewiczL. K.1996; Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B. J Med Virol 49:124–131[CrossRef]
KagiD.,
VignauxF.,
LedermannB.,
BurkiK.,
DepraetereV.,
NagataS.,
HengartnerH.,
GolsteinP.1994; Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528–530[CrossRef]
KataokaT.,
ShinoharaN.,
TakayamaH.,
TakakuK.,
KondoS.,
YoneharaS.,
NagaiK.1996; Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156:3678–3686
KhanolkarA.,
YagitaH.,
CannonM. J.2001; Preferential utilization of the perforin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblastoid cells by virus-specific CD4+ T cells. Virology 287:79–88[CrossRef]
KomanduriK. V.,
ViswanathanM. N.,
WiederE. D.,
SchmidtD. K.,
BredtB. M.,
JacobsonM. A.,
McCuneJ. M.1998; Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:953–956[CrossRef]
Le RoyE.,
Muhlethaler-MottetA.,
DavrincheC.,
MachB.,
DavignonJ. L.1999; Escape of human cytomegalovirus from HLA-DR-restricted CD4+ T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. J Virol 73:6582–6589
Le RoyE.,
BaronM.,
FaigleW.,
ClementD.,
LewinsohnD. M.,
StreblowD. N.,
NelsonJ. A.,
AmigorenaS.,
DavignonJ. L.2002; Infection of APC by human cytomegalovirus controlled through recognition of endogenous nuclear immediate early protein 1 by specific CD4+ T lymphocytes. J Immunol 169:1293–1301[CrossRef]
LondeiM.,
LambJ. R.,
BottazzoG. F.,
FeldmannM.1984; Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature 312:639–641[CrossRef]
MedemaJ. P.,
de JongJ.,
PeltenburgL. T.,
VerdegaalE. M.,
GorterA.,
BresS. A.,
FrankenK. L.,
HahneM.,
AlbarJ. P. & other authors (2001a). Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci U S A 98:11515–11520[CrossRef]
MedemaJ. P.,
SchuurhuisD. H.,
ReaD.,
van TongerenJ.,
de JongJ.,
BresS. A.,
LabanS.,
ToesR. E.,
ToebesM.other authors2001b; Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med 194:657–667[CrossRef]
MillerD. M.,
CebullaC. M.,
SedmakD. D.2002; Human cytomegalovirus inhibition of major histocompatibility complex transcription and interferon signal transduction. Curr Top Microbiol Immunol 269:153–170
MocarskiE. S., Jr.
2004; Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6:707–717[CrossRef]
OdebergJ.,
BrowneH.,
MetkarS.,
FroelichC. J.,
BrandenL.,
CosmanD.,
Soderberg-NauclerC.2003; The human cytomegalovirus protein UL16 mediates increased resistance to natural killer cell cytotoxicity through resistance to cytolytic proteins. J Virol 77:4539–4545[CrossRef]
SinzgerC.,
PlachterB.,
GrefteA.,
TheT. H.,
JahnG.1996; Tissue macrophages are infected by human cytomegalovirus in vivo. J Infect Dis 173:240–245[CrossRef]
SinzgerC.,
KahlM.,
LaibK.,
KlingelK.,
RiegerP.,
PlachterB.,
JahnG.2000; Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry step dependent on efficient translocation to the nucleus. J Gen Virol 81:3021–3035
SylwesterA. W.,
MitchellB. L.,
EdgarJ. B.,
TaorminaC.,
PelteC.,
RuchtiF.,
SleathP. R.,
GrabsteinK. H.,
HoskenN. A.other authors2005; Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202:673–685[CrossRef]
TomazinR.,
BonameJ.,
HegdeN. R.,
LewinsohnD. M.,
AltschulerY.,
JonesT. R.,
CresswellP.,
NelsonJ. A.,
RiddellS. R.,
JohnsonD. C.1999; Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med 5:1039–1043[CrossRef]
Vales-GomezM.,
BrowneH.,
ReyburnH. T.2003; Expression of the UL16 glycoprotein of human cytomegalovirus protects the virus-infected cell from attack by natural killer cells. BMC Immunol 4:4[CrossRef]
ValituttiS.,
MullerS.,
DessingM.,
LanzavecchiaA.1996; Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 183:1917–1921[CrossRef]
van LeeuwenE. M.,
RemmerswaalE. B.,
VossenM. T.,
RowshaniA. T.,
Wertheim-van DillenP. M.,
van LierR. A.,
ten BergeI. J.2004; Emergence of a CD4+CD28− granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 173:1834–1841[CrossRef]
WalterE. A.,
GreenbergP. D.,
GilbertM. J.,
FinchR. J.,
WatanabeK. S.,
ThomasE. D.,
RiddellS. R.1995; Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038–1044[CrossRef]
WarrenA. P.,
DucroqD. H.,
LehnerP. J.,
BorysiewiczL. K.1994; Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes. J Virol 68:2822–2829
WeekesM. P.,
WillsM. R.,
SissonsJ. G.,
CarmichaelA. J.2004; Long-term stable expanded human CD4+ T cell clones specific for human cytomegalovirus are distributed in both CD45RAhigh and CD45ROhigh populations. J Immunol 173:5843–5851[CrossRef]
YasukawaM.,
YakushijinY.,
FujitaS.1996; Two distinct mechanisms of cytotoxicity mediated by herpes simplex virus-specific CD4+ human cytotoxic T cell clones. Clin Immunol Immunopathol 78:70–76[CrossRef]
ZaundersJ. J.,
DyerW. B.,
WangB.,
MunierM. L.,
Miranda-SaksenaM.,
NewtonR.,
MooreJ.,
MackayC. R.,
CooperD. A.other authors2004; Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood 103:2238–2247[CrossRef]